Loading company
Rhythm Pharmaceuticals, Inc.
RYTM · Nasdaq · ·
Next earnings: November 3, 2026
$95.72-2.8%Sep 29 close
- 1M
- -10.7%
- 6M
- +23.9%
- 1Y
- -5.2%
- 5Y
- +595.1%
RYTM · Nasdaq · ·
Next earnings: November 3, 2026
$95.72-2.8%Sep 29 close
Rhythm Pharmaceuticals, Inc. is scheduled to report next on November 3, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $71.3M | $48.5M | +46.91% |
| Profit | -$49.3M | -$46.6M | -5.72% |
| Profit per share | -$0.73 | -$0.75 | +2.67% |
| Free Cash Flow | -$29.4M | -$34M | +13.58% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“Rhythm continues to demonstrate strong commercial and clinical development progress, highlighted by a strong start in the U.S. launch of IMCIVREE for acquired hypothalamic obesity (HO),”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
RM-718 is an investigational, weekly-injectable, MC4R-specific agonist that has demonstrated the potential to reduce body weight and hunger in preclinical studies. RM-718 is designed to be highly selective and MC1R-sparing and thereby reducing the frequency and severity of hyperpigmentation. Conference Call Information Rhythm Pharmaceuticals will host a live conference call and webcast at 8:00 a.m. ET today to review its second quarter 2026 financial results and recent business activities. Participants may register for the conference call here . It is recommended that participants join the call ten minutes prior to the scheduled start. A webcast of the call will also be available under "Events and Presentations" in the
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Rhythm Pharmaceuticals, Inc.’s Item 2.02 8-K filed August 4, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Rhythm Pharmaceuticals, Inc. has no earnings call transcript available.